

CALEB J. BANTA-GREEN, PHD MPH MSW

Addictions, Drug & Alcohol Institute (formerly Alcohol & Drug Abuse Institute)

Department of Psychiatry and Behavioral Sciences, School of Medicine

University of Washington

1107 NE 45th St, Suite 120 Seattle WA 98105 UW Box #354805

206-685-3919 (ph) 206-245-8524 (cell) calebbg@uw.edu

https://adai.uw.edu/staff_members/caleb-banta-green/

https://depts.washington.edu/hserv/faculty/Banta-Green_Caleb

Citizenship: United States Place of birth: Seattle, WA, USA

EDUCATION

06/08	PhD	Public Health- Health Services Research Evaluation Sciences Concentration	University of Washington, Seattle, WA
06/97	MPH	Public Health- Maternal and Child Health	University of Washington, Seattle, WA
06/96	MSW	Social Work	University of Washington, Seattle, WA
06/93	BA	Biology	University of California, Santa Cruz, CA

Dissertation

Opioid drug abuse treatment-Factors associated with opioid use type and retention in treatment.

Committee: Charles Maynard PhD; Thomas Koepsell MD MPH; Paul Fishman PhD; Dennis Donovan PhD 2008 Department of Health Services (now Health Systems & Population Health), School of Public Health, University of Washington

PROFESSIONAL POSITIONS

Research Professor, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington. June 2023–present

Acting Professor, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington. August 2022–May 2023

Director, Center for Community-Engaged Drug Education, Epidemiology & Research, Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington. August 2022–present

Affiliate Professor, School of Public Health, University of Washington. July 2021–July 2022
(Transitioning to *adjunct* appointment)

Principal Research Scientist, Addictions, Drug & Alcohol Institute, University of Washington. 2016–2022

Interim Director, Alcohol & Drug Abuse Institute, University of Washington. September 2018–June 2019

Affiliate Associate Professor, School of Public Health, University of Washington. 2014–June 2021

Affiliate Faculty, Harborview Injury Prevention & Research Center, University of Washington. 2014–present

Senior Science Advisor, Office of National Drug Control Policy, Executive Office of the President. 2012

Affiliate Assistant Professor, School of Public Health, University of Washington. 2012–2014

Senior Research Scientist, Alcohol & Drug Abuse Institute, University of Washington. 2012–2016

Research Scientist, Alcohol & Drug Abuse Institute, University of Washington. 2003–2012

Research Consultant, Alcohol & Drug Abuse Institute, University of Washington. 2001–2003
Program Analyst, Casey Family Programs, Seattle, WA. 1999–2001
Research Coordinator, Alcohol & Drug Abuse Institute, University of Washington. 1997–1999
Project Coordinator, Alcohol & Drug Abuse Institute, University of Washington, Seattle, WA. 1996-1997
Social Work Intern, Veterans Affairs Medical Center, Seattle, WA. 1995
Social Work Intern, Evergreen Treatment Services (Opiate treatment program), Seattle, WA. 1995
Health Educator & Nursing Assistant, Planned Parenthood, Seattle and Kirkland, WA 1993-1994

HONORS, AWARDS, SCHOLARSHIPS

Community Connector Award, WA State Recovery Helpline, 2018
Friend of Pharmacy Award, Washington State Pharmacy Association, 2017
Annual Public Health Leadership Award, Washington State Department of Health, 2016
Annual Lectureship in Toxicology, American Academy of Forensic Sciences, 2014
College on Problems of Drug Dependence Travel Award 2013
National Research Service Award (T32), Agency for Healthcare Research and Quality, Health Services Research Traineeship 2005-2006
Public Health- Seattle & King County- Enhancing the Field Award 2006
University of Washington Tobacco Studies Program, Career Development Stipend 2005

DIVERSITY, EQUITY, AND INCLUSION ACTIVITIES

I work to be explicitly anti-racist in the topics I choose to study, how I study them, and how I talk about substance use with students, colleagues, the general public, and the media. Stigmatized polices and substance use treatment modalities are inextricably linked to race, class, gender identity, and sexual orientation in the United States. Some examples of my long-time commitment to DE&I include:

- Early clinical social work training and research with highly stigmatized and marginalized populations with substance use disorder including those who use heroin and men who have sex with men and inject methamphetamine.
- Working at Planned Parenthood to ensure equitable access to health education, supplies, health care for all people with an emphasis on serving women and low income people.
- Participating in and presenting at community-based meetings with tribal communities across Washington State about drug epidemiology, evidence-based interventions, and culturally adapting services and policies. I have visited and participated in presentations and community meetings with tribes including Lummi, Tulalip, Muckleshoot, Makah, Port Gamble S’Klallam, Puyallup, and Suquamish, and have presented to the American Indian Health Commission.
- Grounding my team’s work in community engaged processes and incorporating, and paying, people with lived/living experience of drug use for their invaluable insights into policy, practice, and research. For my 2022 NIH grant I have hired a person with lived experience of substance use to participate in all aspects of project design, implementation, oversight and evaluation. We are early in this work and actively working to improve our processes.
- Promoting and researching harm reduction and shared decision making as services and ways of engaging with people that support their autonomy and agency to decide their care. These approaches help address structural and relational barriers and inequities to humane, person-centered care.

- Sponsoring the annual Transforming our Communities gatherings. The planning committee is a diverse group of people from across Washington State with lived/living experiences of substance use with diverse identities. The titles of our past three gatherings are illustrative of our intent:
 - Health, Equity, and Justice for People Who Use Drugs, 2020
 - Supporting People who Use Drugs, 2021
 - Sharing Innovations to Reduce Harms for People Who Use Drugs, 2022

PROFESSIONAL ORGANIZATIONS

Regular Member, College on Problems of Drug Dependence	2021-Current
Associate Member, College on Problems of Drug Dependence	2011-2020
American Public Health Association	2003-2006

TEACHING

Course lectures

Epidemiology 506 Surveillance Systems And Decision Making In Public Health *Presentations on current opioid overdose epidemiology and surveillance data systems.* 4/20/18, 5/17/19, 5/6/21, 4/22/22, 5/19/22

MGMT 320 Business, Government and Society *Opioid use, misuse, and consequences in WA State 2001-2021 the impact of health systems and public health responses.* 1/18/2022

Conjoint 556 Addiction: Mechanisms, Treatment, Prevention *The Opioid Crisis: How did we get here? Why is opioid use disorder treatment controversial?* [Course evaluations available] 10/5/17, 1/20/22

Oral medicine 651 Health and Homelessness *Dentists' role in preventing substance use disorder and overdose & providing appropriate services to patients with problematic substance use* 10/04/2021

Public Health Injury Epidemiology- *Opiate Morbidity & Mortality: epidemiology, prevention and interventions* 11/05/14

Maternal and Child Health Seminar- *Talking research with media- Why and How* 4/25/11, 1/1/13 and 11/14/14

Health Services 525 *Multivariate Imputation with Chained Equations- An Example in STATA* 04/21/09

Oral medicine 651 Health and Homelessness *Harm reduction for opioid use and abuse in WA State* 2/6/14

Social Work 460 Addiction – Trends in Drug Abuse 4/14/08

Regular presentations to UW medicine student groups; UWMC and Harborview clinics and grand rounds; and Health Point, NeighborCare, Swedish, Providence and other health systems and health care payers.

Regular presentations for UW telemedicine consultation programs including TelePain, Psychiatry and Addictions Case Conference, Project ECHO HCV, and the now defunct Rural Opioid Addiction Medicine tele-medicine series.

Advisory committees, Student advising and formal mentoring

Dissertation committee member Adam Palayew (UW SPH Epi), 2021-Current *Feasibility and Acceptability of Different Models of Safe Supply and Their Modeled Potential Impact on Overdoses, Overdose Deaths, and Economic Costs*

Dissertation committee member Haylea Hannah (UW SPH Epi), *Opioid use disorder treatment medications in California jails, 2019-2022.*

MPH Practicum Faculty Advisor (UW SPH HServ), Sierra Teadt Jan 2021-June 2021.

Mentor NIH NIDA K23, Lauren Whiteside MD MPH (University of Washington, Harborview Medical Center Emergency Medicine) *A longitudinal collaborative care model for patients with prescription opioid misuse utilizing the Emergency Department for care* 2015-2021

Chair, dissertation committee for Vanessa McMahan (UW SPH HServ) *Evaluating Interest and Uptake of Methamphetamine Reduction and Pre-exposure Prophylaxis (PrEP) Interventions among Cismen who Have Sex with Men (MSM) and Injection Drug Users (IDU) who Use Methamphetamine.* 2016-2019

Chair, MPH thesis committee for Connor Henry (UW SPH HServ) *Qualitative Analysis of Treatment Barriers for Syringe Exchange* 2019

MPH Practicum Faculty Advisor (UW SPH HServ), Joshua Edrich 2019

MPH Student Advisor (UW SPH HServ), Connor Henry 2018-2019

Chair, MPH thesis committee for Madeline Frost (UW SPH HServ) *Factors associated with interest in drug treatment among syringe exchange clients who use opioids* 2017

Chair, MPH thesis (UW SPH Epi), John Haight, *Seattle Police Department – Naloxone Evaluation*, 2016-17

Medical Student Research Training Program (UW School of Medicine MSRTP), Elly Riser (Osborn), *Mason County overdose reversal formative assessment*, 2016

MPH Thesis Committee Chair, Derek Low (UW SPH HServ), *Factors associated with interest in a medically supervised drug use facility among King County drug injectors*, 2013

MPH Thesis Committee, Emily Cederbaum (UW SPH HServ), *Characteristics of syringe exchange users- Age and gender analyses.* 2013

MPH Student Advisor, Stephanie Roe (UW SPH HServ), *An Initial Evaluation of Web-Based Opioid Overdose Education*, 2012-2013

Medical student research project advisor, Peter G. Edminster, *Path through the wilderness: implementing Buprenorphine replacement therapy versus take-home Naloxone programs for prevention of opiate overdose in rural communities.* 2013

SPECIAL NATIONAL RESPONSIBILITIES

Advisory committees, Workgroups, Editing

Member, U.S. Department of Health and Human Services, Interdepartmental Substance Use Disorders Coordinating Committee	2020-Present
O'Neill Institute for National and Global Health Law at Georgetown University, Addiction & Public Policy Initiative Advisory Committee	2019-Present
Association of Schools and Programs of Public Health, Task Force on Public Health Initiatives to Address the Substance Abuse Crisis	2019
Scientific Advisory Group, National Drug Early Warning System, National Institutes of Health, National Institute on Drug Abuse	2015–2020
Technical Editor, Assessing Drug Abuse Within and Across Communities, Community National Institutes of Health, National Institute on Drug Abuse (NIH NIDA) pub. no. 06-3614)	2006

Scientific review- Grants

National Institutes of Health, National Institute on Drug Abuse ad hoc grant reviewer. Most recently: HEAL Special Emphasis Panel 6/1 & 6/16/2022	2016-Current
Centers for Disease Control and Prevention, ad hoc grant reviewer	2014-Current

SPECIAL LOCAL RESPONSIBILITIES

Advisory committees, Workgroups, Conference planning, Editing

Member, WA State ESB5476 Substance Use and Recovery Services Advisory Committee	2021-Present
Center for Rural Opioid Prevention, Treatment, and Recovery (CROP+TR) at Washington State University, Advisory board member	2020-Present
Chair, Data Safety Monitoring Board <i>Repeated-dose Behavioral Intervention to Reduce Opioid Overdose: A Two-Site Randomized-Controlled Efficacy Trial (REBOOT)</i> Study, UCSF IRB #17-24203 PI: Phillip Coffin.	2018-Present
International Community Corrections Association Conference - Doing What Matters: Integrating Public Health and Criminal Justice Reforms. Research Co-Chair. Seattle, WA	2017
Co-Executive Sponsor, Washington State Opioid Response Workgroup	2016-Present
Co-Chair Treatment & Evaluation Committees King County Opioid Task Force	2016-Present
Member, King County Heroin and Opioid Addiction Task Force	2016
Testing the waters: First international multidisciplinary conference on detecting illicit drugs in wastewater. Conference Scientific Board, Lisbon, Portugal	2013
Injury Control and Prevention Workgroup, Washington State Dept. of Health	2012-2013
Epidemiological Outcomes Workgroup, Washington State Dept. of Health	2011-2016
WA State Department of Health Opiate Morbidity and Mortality Workgroup	2008-Present
Seattle/King County representative to National Drug Epidemiology Workgroup NIH NIDA	2001-Present

University of Washington Service

ADAI Director Hiring Committee at the request of Health Sciences Administration	2018-2019
ADAI Small Grants Ad hoc reviewer	2015-Current
UW Human Subjects Review Committee	2011-2012
Ad hoc policy and legislative reviews and testimony on behalf of UW School of Medicine Government Relations	2009-Current

FUNDING HISTORY

Current projects

Using data to drive action to reduce opioid overdoses in Seattle, WA
NIH NIDA 1 R61DA057600 Banta-Green & Hood (Co-PI)
Role: Co-PI 25% Years 1-5
\$4,005,282 09/01/2022 - 08/31/2027 (Two phase grant with first year funded)

Medication-First Delivery for High-Acuity Opioid Use Disorder Populations, Multi-site trial
The Paul G. Allen Family Foundation, Banta-Green
Role: PI 40%
\$4,250,000 12/21/18-04/30/2023

Nurse care manager funding at syringe exchange programs (Work order 2)
Washington State Health Care Authority
Role: PI 0% (Funds to support nurse care manager services to complement Allen Foundation grant)
\$4,936,603 07/01/2019-06/30/2023

Center for Drug Safety & Services Education (Work order 1)
WA Health Care Authority DBHR, Banta-Green
Role: PI 10%
\$1,474,680 10/01/2015-06/30/2023

State Opioid Response Training and Technical Assistance
WA HCA DBHR Fuchs
Role: PI of Subaward for contract from SAMHSA 20%
\$500,000 01/01/2019-09/29/2023 (Funded amount for current Federal fiscal year)

Emergency Department Longitudinal Integrated Care (ED-LINC)
NIH NIDA R01 Whiteside (PI)
Role: Co-Investigator 5%
\$793,084 06/01/2021 to 06/30/2026

Completed projects

Medication-First Delivery for High-Acuity Opioid Use Disorder Populations, Rural clinical supports Premera
Role: PI 0% (Funds to support rural clinical services to complement Allen Foundation grant)
\$1,500,000 08/01/2019-05/31/2022

Washington State Project to Prevent Prescription Drug/Opioid Overdose (WA-PDO)
SAMHSA H79 SP022135 Long (PI)
Role: PI of Subaward from WA Health Care Authority 5%
~80% annually of total \$1,000,000 annually awarded to HCA 09/01/16–08/31/21

Interventions to Improve the HIV PrEP Cascade among Methamphetamine Users
NIH NIDA R34 DA045620 Stekler (PI)
Role: Co-Investigator 2%
\$349,000 08/01/17–09/07/21

King County Opioid Treatment Access Program (KCOTAP)
SAMHSA H79 SP080958 Shim (PI)
Role: PI of Subaward 2%
\$25,055 09/30/18–09/29/21

State Treatment Response (STR) Technical Assistance
DSHS/DBHR1365-90004 Task Order J Caleb Banta-Green
Role: PI of Subcontract for parent award from DHHS SAMHSA 5%
\$118,182 08/01/2017 – 04/30/2019

Prescription Drug Overdose Prevention for States
Washington State Department of Health (DOH) HED22101 Caleb Banta-Green
Role: PI of Subcontract for parent award from CDC 30%
\$108,747 09/01/2017 – 08/31/2018

WA State Innovation Initiative- Medication Assisted Treatment upon Release from Prison
Laura and John Arnold Foundation Caleb Banta-Green
Role: PI 25%
\$265,417 08/02/2016 – 02/28/2019

Seattle Police Department Naloxone Evaluation
Seattle Police Department Caleb Banta-Green
Role: PI 10%
\$25,000 02/01/2016 to 01/31/2017

Impacts of Cannabis & Cannabis Legalization on Impaired Driving in WA State
AAA Foundation for Traffic Safety Multiple PI Caleb Banta-Green & Ali Rowhani-Rahbar
Role: Contact PI 25%
\$199,832 07/02/2014-12/31/2015

Evaluation of Initial WA DOH PMP Implementation
Washington State Department of Health (N20200) Caleb Banta-Green
Role: PI of sub-contract 10%
\$93,897 8/1/13 – 7/31/14

The Drugged Driving Information Service (DDIS)
National Institute on Drug Abuse (HHSN271201200014C) William Luchansky
Role: PI of sub-contract 20%
\$45,000 8/20/12 – 5/19/13

A Trial to Prevent Opioid Overdose: E.D. Based Intervention & Take-Home Naloxone.
National Institute on Drug Abuse (R01 DA030351) Caleb Banta-Green
Role: PI 35%
\$1,762,386 05/15/2012-04/30/2017

Developing Overdose Prevention Programs for Washington State
Washington State Office of the Attorney General Caleb Banta-Green
Role: PI 20%
\$53,375, 7/1/12 – 6/30/13

Evaluation of a Public Health Law to Support Intervening in Drug Overdose
Robert Wood Johnson Foundation (RWJF # 68396) Caleb Banta-Green & Patricia Kuszler
Role: Corresponding PI 30%
\$133,201, 11/15/10 – 5/14/12

ADepT GIS: Alcohol and Drug Epidemiology and Treatment Geographic Information Service
National Institute on Drug Abuse (HHSN271200800021C) Joseph Kabel
Role: PI of sub-contract 20%
\$48,791, 8/1/08 – 7/14/11

Clinical Trials Network: Pacific Northwest Node
Protocol: Methamphetamine: Where Does It Fit in the Bigger Picture of Drug Use of American Indian
and Alaska Native Communities and Treatment Seekers?
National Institute on Drug Abuse (U10 DA013714) Dennis M. Donovan
Role: Analyst 10%
\$1,726,070, 9/1/07 – 8/31/08

Long-term Opioid Management of Chronic Pain: Trends and Risks
National Institute on Drug Abuse (R01 DA022557) Michael Von Korff
Role: Co-I 10%
9/30/06 – 4/30/11

Toxicology Lab Data Epidemiology
Washington State Patrol Forensic Laboratory (C060640GSC / UW) Caleb Banta-Green
Role: PI of Sub-Contract 20%
\$81,898, 1/18/06 – 12/31/07

Prescription Opioid Misuse in a Large HMO
National Institute on Drug Abuse (R21 DA018695) Caleb Banta-Green
Role: PI 30%
\$362,500, 6/10/06 – 5/31/09

Ecstasy, Other Club Drugs, Methamphetamine & Inhalant Prevention Infrastructure Development
Public Health Seattle & King County D32766D (sub of 1 U79 SP10004 DHHS CSAP) Caleb Banta-Green
Role: PI Sub-Contract 30%
\$40,724, 1/1/03 – 2/29/04

Substance Abuse Epidemiology
Department of Social & Health Services (7474) Dennis M. Donovan, Ph.D.
Role: Research Consultant 100% (Started 11/19/01)
\$68,390, 3/1/01 – 12/31/02

BIBLIOGRAPHY

Google Scholar 6,459 citations, h-index 32 as of 06/22/2023.

Refereed research articles (*Mentored student papers)

1. Fockele CE, Morse SC, van Draanen J, Leyde S, **Banta-Green C**, Huynh LN, Zatzick A, Whiteside LK. *"That Line Just Kept Moving": Motivations and Experiences of People Who Use Methamphetamine*. West J Emerg Med. 2023 Feb 25;24(2):218-227. doi: 10.5811/westjem.2022.12.58396. PMID: 36976607; PMCID: PMC10047723.
2. Peavy, K.M., Adwell, A., Owens, D.O., **Banta-Green, C.J.** (2023). *Perspectives on medication treatment for opioid use disorder in adolescents: Results from a learning series supporting providers*. Subst Use Misuse. 58(1):160-162. doi: 10.1080/10826084.2022.2136493.
3. **Banta-Green, C.J.**, Owens, M.D., Williams, J.W., Sears, J.M., Floyd, A.S., Williams-Gilbert, W., and Kingston, S. (2022). *The Community-Based Medication-First program for opioid use disorder: A hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State*. Addiction Science & Clinical Practice 17 (1). DOI: 10.1186/s13722-022-00315-4
4. Owens, M.D., **Banta-Green, C.J.**, Newman, A., Marren, R. and Takushi, R. (2022). *Insights into a Recovery Community Center Model: Results from Qualitative Interviews with Staff and Member Facilitators from Recovery Cafe in Seattle, Washington*. Alcoholism Treatment Quarterly, DOI: 10.1080/07347324.2022.2088323
5. Whiteside, L.K., Huynh, L., Morse, S., Hall, J., Meurer, W., **Banta-Green, C.J.**, Scheuer, H., Cunningham, R., McGovern, M., and Zatzick, D.F. (2022). *The Emergency Department Longitudinal Integrated Care (ED-LINC) intervention targeting opioid use disorder: A pilot randomized clinical trial*. J Subst Abuse Treat. 136:108666. doi: 10.1016/j.jsat.2021.108666.
6. **Banta-Green, C.J.**, Hansen, R.N., Ossiander, E.M., Wasserman, C.R. and Merrill, J.O. (2021). *Buprenorphine utilization among all Washington State residents' based upon prescription monitoring program data- Characteristics associated with two measures of retention and patterns of care over time*. J Subst Abuse Treat. 15:108446. doi: 10.1016/j.jsat.2021.108446.

7. *McMahan VM, Kingston S, Newman A, Stekler JD, Glick SN, **Banta-Green CJ**. *Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State*. Drug Alcohol Depend. 2020 Nov 1; 216:108243. doi: 10.1016/j.drugalcdep.2020.108243. Epub 2020 Aug 23. PubMed PMID: 32911134.
8. McMahan VM, Frank N, Buckler S, Violette LR, Baeten JM, **Banta-Green CJ**, Barnabas RV, Simoni J, Stekler JD. *Protocol Development for HMU! (HIV Prevention for Methamphetamine Users), a Study of Peer Navigation and Text Messaging to Promote Pre-Exposure Prophylaxis Adherence and Persistence Among People Who Use Methamphetamine: Qualitative Focus Group and Interview Study*. JMIR Form Res. 2020 Sep 14;4(9):e18118. doi: 10.2196/18118. PubMed PMID: 32924952; PubMed Central PMCID: PMC7522731.
9. **Banta-Green CJ**, Williams JR, Sears JM, Floyd AS, Tsui JI, Hoeft TJ. *Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder*. Drug Alcohol Depend. 2020 Feb 1;207:107799. doi: 10.1016/j.drugalcdep.2019.107799. Epub 2019 Dec 11. PubMed PMID: 31865058.
10. Hood JE, **Banta-Green CJ**, Duchin JS, Breuner J, Dell W, Finegood B, Glick SN, Hamblin M, Holcomb S, Mosse D, Oliphant-Wells T, Shim MM. *Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington*. Subst Abus. 2020;41(3):356-364. doi: 10.1080/08897077.2019.1635557. Epub 2019 Aug 12. PubMed PMID: 31403907.
11. **Banta-Green CJ**, Floyd AS, Vick K, Arthur J, Hoeft TJ, Tsui JI. *Opioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility Study*. Subst Abuse Rehabil. 2019;10:57-67. doi: 10.2147/SAR.S192045. eCollection 2019. PubMed PMID: 31695555; PubMed Central PMCID: PMC6815213.
12. Burgard DA, Williams J, Westerman D, Rushing R, Carpenter R, LaRock A, Sadetsky J, Clarke J, Fryhle H, Pellman M, **Banta-Green CJ**. *Using wastewater-based analysis to monitor the effects of legalized retail sales on cannabis consumption in Washington State, USA*. Addiction. 2019 Sep;114(9):1582-1590. doi: 10.1111/add.14641. Epub 2019 Jun 18. PubMed PMID: 31211480; PubMed Central PMCID: PMC6814135.
13. **Banta-Green CJ**, Coffin PO, Merrill JO, Sears JM, Dunn C, Floyd AS, Whiteside LK, Yanez ND, Donovan DM. *Impacts of an opioid overdose prevention intervention delivered subsequent to acute care*. Inj Prev. 2019 Jun;25(3):191-198. doi: 10.1136/injuryprev-2017-042676. Epub 2018 Feb 7. PubMed PMID: 29436397; PubMed Central PMCID: PMC6800078.
14. Hood JE, Behrends CN, Irwin A, Schackman BR, Chan D, Hartfield K, Hess J, **Banta-Green C**, Whiteside L, Finegood B, Duchin J. *The projected costs and benefits of a supervised injection facility in Seattle, WA, USA*. Int J Drug Policy. 2019 May;67:9-18. doi: 10.1016/j.drugpo.2018.12.015. Epub 2019 Feb 23. PubMed PMID: 30802842.
15. McMahan VM, Martin A, Garske L, Violette LR, Andrasik MP, Baeten JM, **Banta-Green C**, Stekler JD. *Development of a targeted educational intervention to increase pre-exposure prophylaxis uptake among cisgender men and transgender individuals who have sex with men and use methamphetamine in Seattle (WA, USA)*. Sex Health. 2019 Apr;16(2):139-147. doi: 10.1071/SH18060. PubMed PMID: 30739638.
16. *Frost MC, Williams EC, Kingston S, **Banta-Green CJ**. *Interest in Getting Help to Reduce or Stop Substance Use Among Syringe Exchange Clients Who Use Opioids*. J Addict Med. 2018 Nov/Dec;12(6):428-434. doi: 10.1097/ADM.0000000000000426. PubMed PMID: 29889118.

17. Hood JE, Buskin SE, Golden MR, Glick SN, Banta-Green C, Dombrowski JC. *The Changing Burden of HIV Attributable to Methamphetamine Among Men Who Have Sex with Men in King County, Washington*. AIDS Patient Care STDS. 2018 Jun;32(6):223-233. doi: 10.1089/apc.2017.0306. PubMed PMID: 29851502.
18. Glick SN, Burt R, Kummer K, Tinsley J, **Banta-Green CJ**, Golden MR. *Increasing methamphetamine injection among non-MSM who inject drugs in King County, Washington*. Drug Alcohol Depend. 2018 Jan 1;182:86-92. doi: 10.1016/j.drugalcdep.2017.10.011. Epub 2017 Nov 16. PubMed PMID: 29175463; PubMed Central PMCID: PMC6457905.
19. Knipper E, **Banta-Green CJ**, Jimenez N. *Opioid use disorder and misuse: A review of the epidemiology and medical implications for pediatric anesthesiologists*. Paediatr Anaesth. 2017 Nov;27(11):1070-1076. doi: 10.1111/pan.13225. Review. PubMed PMID: 29030938.
20. **Banta-Green CJ**, Coffin PO, Schoeppe JA, Merrill JO, Whiteside LK, Ebersol AK. *Heroin and pharmaceutical opioid overdose events: Emergency medical response characteristics*. Drug Alcohol Depend. 2017 Sep 1;178:1-6. doi: 10.1016/j.drugalcdep.2017.04.021. Epub 2017 Jun 10. PubMed PMID: 28623805.
21. **Banta-Green CJ**, Brewer AJ, Ort C, Helsel DR, Williams JR, Field JA. *Using wastewater-based epidemiology to estimate drug consumption-Statistical analyses and data presentation*. Sci Total Environ. 2016 Oct 15;568:856-863. doi: 10.1016/j.scitotenv.2016.06.052. Epub 2016 Jun 20. PubMed PMID: 27338844.
22. Brewer AJ, **Banta-Green CJ**, Ort C, Robel AE, Field J. *Wastewater testing compared with random urinalyses for the surveillance of illicit drug use in prisons*. Drug Alcohol Rev. 2016 Mar;35(2):133-7. doi: 10.1111/dar.12185. Epub 2014 Aug 7. PubMed PMID: 25100044; PubMed Central PMCID: PMC4465406.
23. *Roe SS, **Banta-Green CJ**. *An Initial Evaluation of Web-Based Opioid Overdose Education*. Subst Use Misuse. 2016 Jan 28;51(2):268-75. doi: 10.3109/10826084.2015.1092986. Epub 2015 Dec 28. PubMed PMID: 26709867.
24. *Cedarbaum ER, **Banta-Green CJ**. *Health behaviors of young adult heroin injectors in the Seattle area*. Drug Alcohol Depend. 2016 Jan 1;158:102-9. doi: 10.1016/j.drugalcdep.2015.11.011. Epub 2015 Nov 17. PubMed PMID: 26651427.
25. Harruff RC, Couper FJ, **Banta-Green CJ**. *Tracking the opioid drug overdose epidemic in King County, Washington using an improved methodology for certifying heroin related deaths*. Acad Forensic Pathol 2015;5(3):499-506. doi: 10.23907/2015.055.
26. Franklin G, Sabel J, Jones CM, Mai J, Baumgartner C, **Banta-Green CJ**, Neven D, Tauben DJ. *A comprehensive approach to address the prescription opioid epidemic in Washington State: milestones and lessons learned*. Am J Public Health. 2015 Mar;105(3):463-9. doi: 10.2105/AJPH.2014.302367. Epub 2015 Jan 20. PubMed PMID: 25602880; PubMed Central PMCID: PMC4330848.
27. **Banta-Green, C.J.**, Beletsky, L., Schoeppe, J., Coffin, P.O. and Kuszler, P. (2013). *Police Officers' and Paramedics' Experiences with Overdose and Their Knowledge and Opinions of Washington State's Drug Overdose-Naloxone-Good Samaritan Law*. J Urban Health. 90(6):1102-11.
28. Brewer, A.J., Ort, C., **Banta-Green, C.J.**, Berset, J.D., Field, J.A. (2012). *Normalized diurnal and between-day trends in illicit and legal drug loads that account for changes in population.. Environ Sci Technol.* 46:8305-14.
29. Merrill, J.O., Von Korff, M., **Banta-Green, C.J.**, Sullivan, M.D., Saunders, K.W., Campbell, C.I., Weisner, C. (2012). *Prescribed Opioid Difficulties, Depression, and Opioid Dose Among Chronic Opioid Therapy Patients*. General Hospital Psychiatry; 34(6):581-7.

30. Howe CQ, Sullivan MD, Saunders KW, Merrill JO, **Banta-Green CJ**, Weisner C, Campbell CI, Von Korff M. (2012). *Depression and ambivalence toward chronic opioid therapy for chronic noncancer pain*. Clin J Pain. 28(7):561-6.
31. Saunders KW, Von Korff M, Campbell CI, **Banta-Green CJ**, Sullivan MD, Merrill JO, Weisner C. (2012). *Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors*. J Pain. 13(3):266-75.
32. Kwamme, E., Catlin, M., **Banta-Green, C.J.**, Roll, J. and Rosenblatt, R. (2012). *Who Prescribes Buprenorphine for Rural Patients: The Impact of Specialty, Location and Practice Type in Washington State*. Journal of Substance Abuse Treatment, 44(3):355-60
33. Radin, S.M., **Banta-Green, C.J.**, Thomas, L.R., Kutz, S.H., and Donovan, D.M. (2012). *Substance Use, Treatment Admissions, and Recovery Trends in Diverse Washington State Tribal Communities*. Am J Drug Alcohol Abuse, 38(5):511-7.
34. * Peavy, K.M., **Banta-Green, C.J.**, Kingston, S., Hanrahan, M., Merrill, J.O., Coffin, P. (2012). *Hooked on prescription-type opiates prior to using heroin: Results from a survey of syringe exchange clients*. Journal of Psychoactive Drugs, 44(3):259-65.
35. Silverberg, M.J., Ray, G.T., Saunders, K., Rutter, C.M., Campbell, C.I., Merrill, J.O., Sullivan, M.D. (2012). **Banta-Green, C.J.**, Von Korff, M., and Weisner, C.. *Prescription long-term opioid use in HIV-infected patients*. Clin J Pain 28:39-46.
36. Pollini, R.A., **Banta-Green, C.J.**, Cuevas-Mota, J., Metzner, M., Teshale, E., and Garfein, R.S. (2011). *Problematic Use of Prescription-Type Opioids Prior to Heroin Use among Young Heroin Injectors*. Substance Abuse and Rehabilitation 2:173-180. PMID: PMC3536052.
37. * Jenkins, L.M., **Banta-Green, C.J.**, Maynard, C., Kingston, S., Hanrahan, M., Merrill, J.O., Coffin, P.O. (2011). *Risk Factors for Nonfatal Overdose at Seattle-area Syringe Exchanges*. J Urban Health. 88: 118-128. PMID: PMC3042084.
38. Chiaia-Hernandez, A.C., **Banta-Green, C.J.**, Field, J.A. (2011). *Interpreting methamphetamine levels in a high-use community*. Environ Sci Pollut Res Int. Apr 21. [Epub ahead of print].
39. **Banta-Green, C.J.**, Von Korff, M., Sullivan, M., Merrill, J.O., Doyle, S., and Saunders, K. (2010). *The Prescribed Opioids Difficulties Scale: A Patient-Centered Assessment of Problems and Concerns*. Clin J Pain. 26: 489-97. PMID: PMC3286631.
40. Campbell CI, Weisner C, Leresche L, Ray GT, Saunders K, Sullivan MD, **Banta-Green CJ**, Merrill JO, Silverberg MJ, Boudreau D, Satre DD, Von Korff M. (2010). *Age and gender trends in long-term opioid analgesic use for noncancer pain*. Am J Public Health.;100(12):2541-7.
41. Dunn, K.M., Saunders, K.W., Rutter, C.M., **Banta-Green, C.J.**, Merrill, J.O., Sullivan, M.D., Weisner, C.M., Silverberg, M.J., Campbell, C.I., Psaty, B.M., and Von Korff, M. (2010). *Opioid Prescriptions for Chronic Pain and Overdose: A Cohort Study*. Annals of Internal Medicine.152: 85-92. PMID: PMC3000551.
42. Sullivan, M.D., Von Korff, M., **Banta-Green, C.**, Merrill, J.O., Saunders, K. (2010). *Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain*. Pain 149: 345-53.
43. **Banta-Green, C.**, Merrill, J.O., Doyle, S., Boudreau, D.M., Calsyn, D.A. (2009). *Measurement of Opioid Problems among Chronic Pain Patients in a General Medical Population*. Drug Alcohol Depend. 104: 43-49. PMID: PMC2716215.
44. **Banta-Green, C.**, Merrill, J.O., Doyle, S., Boudreau, D.M., Calsyn, D.A. (2009). *Opioid use behaviors, mental health and pain-Development of a typology of chronic pain patients*. Drug Alcohol Depend.104:34-42. PMID: PMC2716214.

45. **Banta-Green, C.J.**, Maynard, C., Koepsell, T., Wells, E., Donovan, D. (2009). *Retention in methadone maintenance drug treatment for prescription type opioid primary users compared to heroin users*. *Addiction* 104: 775-783.
46. **Banta-Green, C.J.**, Field, J.A., Chiaia, A.C., Sudakin, D.L., Power, L., de Montigny, L. (2009). *The spatial epidemiology of cocaine, methamphetamine and MDMA use: A demonstration using a population measure of community drug load derived from municipal wastewater*. *Addiction* 104: 1874-1880. PMID: PMC3225199.
47. Braden JB, Sullivan MD, Ray GT, Saunders K, Merrill J, Silverberg MJ, Rutter CM, Weisner C, **Banta-Green C**, Campbell C, Von Korff M. (2009). *Trends in long-term opioid therapy for noncancer pain among persons with a history of depression*. *Gen Hosp Psychiatry*. 31(6):564-70.
48. Boudreau, D., Von Korff, M., Rutter, C. M., Saunders, K., Ray, G.T., Sullivan, M.D., Campbell, C.I., Merrill, J.O., Silverberg, M.J., **Banta-Green, C.**, Weisner C. (2009). *Trends in long-term opioid therapy for chronic non-cancer pain*. *Pharmacoepidemiol Drug Saf*. 31:564-570. PMID: PMC2774904.
49. Chiaia, A.C., **Banta-Green, C**, Field, J. (2008). *Eliminating Solid Phase Extraction with Large-Volume Injection LC/MS/MS: Analysis of Illicit and Legal Drugs and Human Urine Indicators in US Wastewaters*. *Environ Sci Technol*. 42: 8841–8848.
50. **Banta-Green, C.**, Goldbaum, G., Kingston, S., Golden, M., Harruff, R. and Logan, B.K. (2005). *Epidemiology of MDMA and associated club drugs in the Seattle area*. *Substance Use and Misuse*; 40(9-10):1295-315.
51. Gorman, E.M., Barr, B., Hansen, A., Robertson, B. and **Green, C.** (1997). *Speed, sex, gay men, and HIV: Ecological and community perspectives*. *Medical Anthropology Quarterly*, 11(4):505-515.

Other published scholarly publications (Commentaries, Editorials, and Letters)

1. Hatch-Maillette MA, Peavy KM, Tsui JI, **Banta-Green CJ**, Woolworth S, Grekin P. (2020). *Rethinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives*. *J Subst Abuse Treat*. Dec 5:108223. doi: 10.1016/j.jsat.2020.108223.
2. Peavy KM, Darnton J, Grekin P, Russo M, **Banta-Green CJ**, Merrill JO, Fotinos C, Woolworth S, Soth S, Tsui JI. *Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program*. *AIDS Behav* 2020;24:2469-2472. doi: 10.1007/s10461-020-02887-1.
3. Williams J, **Banta-Green C**, Burgard D. *The need for better marijuana sales data*. *Addiction*. 2017 Dec;112(12):2179-2180. doi: 10.1111/add.14037. PubMed PMID: 29105917.
4. Doe-Simkins M, **Banta-Green C**, Davis CS, Green TC, Walley AY. *Comments on Strang et al. (2016): 'Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'*. *Addiction*. 2016 Oct;111(10):1879-80. doi: 10.1111/add.13399. Epub 2016 Jul 14. PubMed PMID: 27412451.
5. **Banta-Green CJ**, Coffin PO. *Commentary on Pierce et al. (2016): Raising the bar of addiction treatment--first do no harm*. *Addiction*. 2016 Feb;111(2):309-10. doi: 10.1111/add.13228. PubMed PMID: 26767339.
6. Davis CS, **Banta-Green CJ**, Coffin P, Dailey MW, Walley AY. *Intranasal Naloxone for Opioid Overdose Reversal*. *Prehosp Emerg Care*. 2015 January-March;19(1):135-137. doi: 10.3109/10903127.2014.942484. Epub 2014 Aug 25. PubMed PMID: 25153260.
7. Coffin P, **Banta-Green C**. *The dueling obligations of opioid stewardship*. *Ann Intern Med*. 2014 Aug 19;161(4):307-8. doi: 10.7326/L14-5016-8. PubMed PMID: 25133372.

8. Burgard DA, **Banta-Green C**, Field JA. *Working upstream: how far can you go with sewage-based drug epidemiology?*. Environ Sci Technol. 2014;48(3):1362-8. doi: 10.1021/es4044648. Epub 2013 Dec 31. PubMed PMID: 24345191.
9. Coffin P, **Banta-Green C**. (2013). *The Dueling Obligations of Opioid Stewardship*. Ann Intern Med. 2013 Dec 10. doi: 10.7326/M13-2781.
10. **Banta-Green, C.J.**, 2012. *Adolescent abuse of pharmaceutical opioids raises questions about prescribing and prevention*. Arch Pediatr Adolesc Med. 166:865-6 (now JAMA Pediatrics)

Reports/Proceedings/Lay magazine articles

1. Kingston S, **Banta-Green C**. *Care Navigation at Harm Reduction Programs: Community-Based "Meds First" Buprenorphine Program Preliminary Data*. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, School of Medicine, University of Washington, June 2022
2. Peavy KM, **Banta-Green C**. *Methadone: An Old Medication with Untapped Potential*. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, University of Washington, April 2022.
3. Kingston S, Newman A, **Banta-Green C**. *Results from the 2021 WA State Syringe Service Program Health Survey*. Seattle, WA: Addictions, Drug & Alcohol Institute, Department of Psychiatry & Behavioral Sciences, University of Washington. March 2022.
4. **Banta-Green CJ**, Williams J. *Dramatic increases in opioid overdose deaths due to fentanyl among young people in Washington State*. Seattle, WA: Addictions, Drug & Alcohol Institute, University of Washington, December 2021.
5. Peavy KM, **Banta-Green C**. *Understanding and Supporting Adolescents with an Opioid Use Disorder*. Seattle, WA: Addictions, Drug & Alcohol Institute (ADAI), University of Washington, June 2021.
6. Peavy KM, **Banta-Green C**. *Group Counseling for People in Medication Treatment for Opioid Use Disorder*. Seattle, WA: Addictions, Drug & Alcohol Institute (ADAI), University of Washington, June 2021.
7. Peavy KM, **Banta-Green C**, Owens M. *Helping People Who Use Opioids and Stimulants*. Seattle, WA: Addictions, Drug & Alcohol Institute, University of Washington, April 2021.
8. Peavy KM, **Banta-Green C**, Owens M. *Opioids and Stimulants: What Are They and How Are People Using Them?* Seattle, WA: Addictions, Drug & Alcohol Institute, University of Washington, April 2021.
9. **Banta-Green C**, Newman A, Kingston S, Glick S, Tinsley J. *Washington State Syringe Exchange Health Survey, 2019 Results*. Seattle, WA: Alcohol & Drug Abuse Institute, University of Washington, 2020.
10. Newman A, Henry C, **Banta-Green CJ**. *"Treat us like individual human beings": 2018 qualitative interviews with Washington State syringe exchange participants*. Alcohol & Drug Abuse Institute, University of Washington, October 2019, 12 p.
11. Newman A, **Banta-Green CJ**. *Peer support groups and medications for opioid use disorder: Perspectives from individuals and care providers*. Alcohol & Drug Abuse Institute, University of Washington, June 2019, 12 p.
12. **Banta-Green CJ**, King County Drug Trends Workgroup. *2018 Drug Trends Report, King County, WA*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, July 2018, 9p.

13. Williams JR, **Banta-Green CJ**. *Opioid Use Estimates: Surveys Use Different Methodologies and Produce Different Estimates*. Seattle: Alcohol and Drug Abuse Institute, University of Washington, December 2018, 5p.
14. Williams JR, Bugard D, **Banta-Green CJ**. *Estimating Cannabinoid Mass Sold from Noisy Cannabis Sales Data*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, June 2018.
15. Stoner SA, Williams JR, Newman A, Sutherland NL, **Banta-Green CJ**. *Methamphetamine in Washington: Report to the Division of Behavioral Health and Recovery*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, June 2018, 35p.
16. **Banta-Green CJ**, Cooley L. *The Role of Medications in the Treatment of Adolescents and Young Adults with Opioid Use Disorder*. Seattle, WA: Alcohol & Drug Abuse Institute, University of Washington, November 2018, 28p.
17. **Banta-Green CJ**, Newman A, Kingston S. *Washington State Syringe Exchange Health Survey: 2017 Results*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, January 2018.
18. **Banta-Green CJ**, Williams JR, King County Community Epidemiology Workgroup. *Drug Use Trends in King County, Washington, 2017*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, May 2018, 14 p.
19. Kingston S, Newman A, **Banta-Green CJ**. *Guide to Fentanyl Surveillance for WA State Syringe Service Programs: Updated April 2017*. ADAI Research Brief, Alcohol & Drug Abuse Institute, University of Washington, April 2017, 3 p.
20. **Banta-Green CJ**, Kingston S. *Washington State Project to Prevent Prescription Drug/Opioid Overdose (WA-PDO): Report on Overdose Education and Naloxone Distribution, Year 1*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, November 2017, 5p.
21. ***Banta-Green CJ**, Haight J. *Seattle Police Department – 2016 Naloxone Evaluation*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, March 2017, 44 p.
22. **Banta-Green CJ**, Williams JR, Smith R, Finegood B, Sylla L, Harruff R, Tinsley J, Munn M, Hood J, Buskin S, Glick S, Freng S, Couper F, Suzuki E, Ohta J, Pugel J, Taylor M. *Drug Use Trends in King County, Washington, 2016*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, July 2017, 14 p.
23. **Banta-Green CJ**, Williams JR. *Opioid Trends in Pierce County*. Report by the Alcohol and Drug Abuse Institute, University of Washington for the Tacoma-Pierce County Health Department, February 2017, 12 p.
24. **Banta-Green CJ**, Vick K, Arthur J. *Medication Safety: Online Resources*. ADAI Research Brief, Alcohol & Drug Abuse Institute, University of Washington, May 2017, 14 p.
25. **Banta-Green CJ**. *Fentanyl Death Investigation in Four Washington State Counties*. ADAI Research Brief, Alcohol & Drug Abuse Institute, University of Washington, May 2017, 6p.
26. Williams JR, **Banta-Green CJ**. *Marijuana use surveys matrix: Different methodologies produce different estimates*. Seattle: Alcohol and Drug Abuse Institute, University of Washington, March 2016.
27. Kingston S, **Banta-Green CJ**. *Results from the 2015 Washington State Drug Injector Health Survey*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, February 2016, 10 p.
28. **Banta-Green CJ**, Jackson TR, Freng S, Hanrahan M, Graff C, Ohta J, Taylor M, Harruff R, Smith R, Sylla L, Miller G, Couper F. *Drug Use Trends in King County, Washington, 2015*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, July 2016, 10pp.
29. **Banta-Green CJ**, Rowhani A, Ebel BE, Andris L, Qiu Q. *Cannabis Use among Drivers Suspected of Driving Under the Influence or Involved in Collisions: Analyses of Washington State Patrol Data*. Washington DC: AAA Foundation for Traffic Safety, May 2016.

30. **Banta-Green CJ**, Rowhani A, Ebel BE, Andris L, Qiu Q. *Marijuana Impaired Driving: Toxicological Testing in Washington State*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, July 2016.
31. Kingston S, **Banta-Green CJ**. *Overview of Syringe Exchange Operations in Washington State*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, September 2015.
32. **Banta-Green CJ**. *Medication assisted treatment for opioid use disorder: Overview of the evidence*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, June 2015.
33. **Banta-Green CJ**. *Opioid trends across Washington state*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, April 2015.
34. **Banta-Green CJ**, Jackson TR, Freng S, Hanrahan M, Graff C, Ohta J, Taylor M, Harruff R, Smith R, Sylla L, Miller G, Couper F. *Drug Abuse Trends in the Seattle/King County Area: 2014*. Seattle: Alcohol & Drug Abuse Institute, University of Washington, June 2015, 12pp.
35. **Banta-Green, C.J.** (2013). Heroin Trends Across Washington State, June 2013. ADAI Info Brief ADAI-IB 2013-02.
36. **Banta-Green CJ**. (2013). *Marijuana Use: Impact in Washington State*. Alcohol & Drug Abuse Institute, University of Washington, June 2013.
37. **Banta-Green CJ**, Field J. *City-wide drug testing using municipal wastewater*. Significance 2011;8(2):70-74
38. **Banta-Green C**, Jackson TR, Knox P, Freng S, Hanrahan M, Albert DH, Ohta J, Forbes A, Smith R, Reid S, Taylor M, Harruff R. *Drug abuse patterns and trends in Seattle, Washington - Update: January 2010. Prepared for the Community Epidemiology Work Group*, Seattle: Alcohol & Drug Abuse Institute, University of Washington, 2010.
39. **Banta-Green CJ**, Jackson TR, Albert DH, Hanrahan M, Taylor M, Freng S, Ohta J, Soukop M, Haruff R, Reid S, Finney E. *Drug Abuse Trends in the Seattle/King County Area: 2009*. / Prepared for the Community Epidemiology Work Group, June 2010. Seattle: Alcohol & Drug Abuse Institute, University of Washington, June 2010, 19 pp.
40. **Banta-Green CJ**, Jackson TR, Albert DH, Hanrahan M, Taylor M, Sookup M, Ohta J, Freng S, Smith R, Forbes A, Harruff R. *Drug Abuse Trends in the Seattle/King County Area: 2008*. / Prepared for the Community Epidemiology Work Group, August 2009. Seattle: Alcohol & Drug Abuse Institute, University of Washington, August 2009, 15 pp.
41. **Banta-Green CJ**, Merrill JO, Jackson TR, Hanrahan M. *The use and abuse of prescription-type opiates in Washington State*. ADAI Info Brief 2007.
42. **Banta-Green CJ**, Jackson TR, Freng S, Hanrahan M, Albert DH, Haruff R, Kingston S, Forbes A, Miller S, Burt R, Thiede H. *Recent drug abuse trends in the Seattle-King County area, June 2007* Seattle: Alcohol & Drug Abuse Institute, University of Washington, June 2007, 17 pp.
43. **Banta-Green CJ**, Jackson TR, Hanrahan M, Freng S, Kingston S, Albert DH, Forbes A, Harruff R, Miller S. *Recent drug abuse trends in the Seattle-King County area, June 2006*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, JUNE 2006: VOLUME II; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 07-5880A). Bethesda, MD: National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, January 2007, 19 p

44. **Banta-Green CJ**, Jackson TR, Hanrahan M, Kingston S, Albert DH, Freng S, Forbes A, Harruff R, Miller S. *Recent drug abuse trends in the Seattle-King County area, January 2006*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, JANUARY 2006: VOLUME II; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 06-5880). Bethesda, MD: National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, September 2006, 13 p.
45. **Banta-Green CJ**, Jackson TR, Hanrahan M, Kingston S, Albert DH, Freng S, Forbes A, Harruff R, Burt R, Thiede H. *Recent drug abuse trends in the Seattle-King County area, June 2005*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, JUNE 2005: VOLUME II; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 06-5282A). Bethesda, MD: National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, March 2006, 28 p.
46. **Banta-Green CJ**, Jackson TR, Hanrahan M, Nyrop K, Freng S, Kingston S, Forbes A, Albert D, Wrede AF, Harruff R, Hewett G. *Recent drug abuse trends in the Seattle-King County area, June 2004*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, JUNE 2004: VOLUME II; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 05-5365A). Bethesda, MD: National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, March 2005, 23 p.
47. **Banta-Green CJ**, Jackson TR, Kingston S, Hanrahan M, Freng S, Albert DH, Forbes A, Nyrop K. *Recent drug abuse trends in the Seattle-King County area, January 2005*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, JANUARY 2005: VOLUME II; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 05-5282). Bethesda, MD: National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, October 2005, 22 p.
48. **Banta-Green C**. "*Club drug" use patterns and related behaviors in Seattle, King County*. Survey data collection for Project STEPS (Stemming the Tide of Ecstasy through Prevention Strategies). Report to Public Health - Seattle & King County, Feb. 9, 2004.
49. **Banta-Green CJ**, Kingston S, Hanrahan M, Miller G, Jackson TR, Forbes A, Wrede AF, Freng S, Harruff R, Hewett G, Nyrop K, McBride M. *Recent drug abuse trends in the Seattle-King County area, June 2003*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, JUNE 2003 : VOLUME II ; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 04-5365A). Bethesda, MD : National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, March 2004, 17 p.
50. **Banta-Green CJ**, Kingston S, Freng S, Miller G, Hanrahan M, Jackson TR, Forbes A, Wrede AF, Harruff R, Hewett G, Nyrop K, McBride M. *Recent drug abuse trends in the Seattle-King County area, December 2003*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, DECEMBER 2003: VOLUME II ; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 04-5365). Bethesda, MD : National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, September 2004, 13 p.
51. **Banta-Green CJ**. *County drug use epidemiology reports: Washington State*. ADAI Info Brief 2004;04-08:15 p.
52. **Banta-Green CJ**, Silverman E, Kingston S, Hanrahan M, Freng S, Jackson TR, Nyrop K, Wrede AF, McBride M, Forbes A, Kabel J, Thiede H, Harruff R, Hewett G. *Recent drug abuse trends in the Seattle-King County area, June 2002*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, JUNE 2002: VOLUME II; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 03-5110A). Bethesda, MD: National Institute on Drug Abuse, Division of Epidemiology, Services & Prevention Research, February 2003, 17 p.

53. **Banta-Green CJ**, Silverman E, Kingston S, Freng S, Hanrahan M, Miller G, Jackson TR, Nyrop K, Wrede AF, McBride M, Harruff R, Hewett G, Forbes A, Kabel J, Thiede H. *Recent drug abuse trends in the Seattle-King County area, December 2002*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, DECEMBER 2002: VOLUME II; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 03-5365). Bethesda, MD: National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, August 2003, 18 p.
54. **Banta-Green CJ**, Merrill J, Jackson TR, Hanrahan M. *Prescription opioid use: Pain management and drug abuse in King County and Washington State*. ADAI Info Brief 2003;2003-03:6p.
55. Silverman E, Wrede AF, **Banta-Green CJ**, Jackson TR, Nyrop K, Freng S, Kingston S, Hanrahan M, Thiede H, Harruff R, Nakagawara J, Fillipi N, McBride M, Forbes A. *Recent drug abuse trends in the Seattle-King County area, December 2001*. IN: Community Epidemiology Work Group. EPIDEMIOLOGIC TRENDS IN DRUG ABUSE, DECEMBER 2001: VOLUME II; PROCEEDINGS OF THE COMMUNITY EPIDEMIOLOGY WORK GROUP (NIH Publication No. 02-5110). Bethesda, MD: National Institute on Drug Abuse, Division of Epidemiology, Services and Prevention Research, May 2002, 11 p. [
56. Rutherford M, **Banta-Green CJ**. *Effectiveness standards for the treatment of chemical dependency in juvenile offenders*. Alcohol & Drug Abuse Institute Technical Report 98-01, Report to the Governor's Office and Legislature of Washington State, 1998.
57. Peterson P, Srebniak D, **Banta-Green CJ**, Baxter B. *Treatment Outcome Evaluation: Youth Admitted to Residential Chemical Dependency Treatment Under the Provisions of the "Becca" Bill*. Report Prepared for the Division of Alcohol and Substance abuse, Washington State Department of Social and Health Services, 1997.
58. Hansten M, **Banta-Green CJ**, Peterson PL. *Evaluation of Washington State Adolescent Detox/Crisis Stabilization Programs*. Report Prepared for the Division of Alcohol and Substance abuse, Washington State Department of Social and Health Services, 1997.

INVITED TALKS (SELECTED)

- National Women and Addiction Group. *Changing legal status and response to drugs; the need for new, more accessible, kind, person-centered, community-based models of care*. Seattle, WA 08/12/22
- Washington State Nursing Care Quality Assurance Commission Conference. *Opioid & stimulant epidemiology, implications for treatment & Nurse care managers for substance use disorder treatment*. 10/12/21.
- Washington State's 70th Governor's Industrial Safety and Health Conference (Virtual, Washington State). *The Opioid Epidemic: Opioid Trends and Treating Use Disorder*. 09/28/21.
- Addiction Fundamental Conference (Virtual, Washington State). *Fentanyl: Rapidly Changing Drug Market, Impacts on Use, Treatment & Overdose*. 3/5/21
- Addiction Fundamental Conference (Virtual, Washington State). *Methamphetamine Trends, Interest in Reducing Use & the Services Desired*. 3/5/21
- Organization of American States, Inter-American Observatory on Drugs. *Early Warning Systems in Response to Opioids and New Psychoactive Substances (NPS) in Latin America and the Caribbean Epidemiological overview of wastewater analysis and drugs*. (Virtual) 10/28/20
- Addiction and Public Policy Initiative at The O'Neill Institute for National and Global Health Law, Georgetown Law *Future State: Addiction Policy, Decarceration, and Connection to Care*, Washington, DC 7/28/2020

National Institute on Justice, U.S. Department of Justice- *Increase the impact: Law enforcement partnerships to improve opioid related interventions* Washington DC 9/25/2018

Judge's workshop Federal Judges of the Western District of Washington- *Treating Opioid Use Disorder with Criminal Justice System Involved People* 5/24/18

Council on State and Territorial Epidemiologists Keynote Lecture- *The opioid epidemic-what you count & how you count it...counts.* Boise, ID 6/15/17

Mathematica 2017 Symposium: The Potential of Wastewater Testing for Public Health and Safety. *Wastewater Testing: A Pipeline to Public Health Data.* Washington DC 5/16/17

King County Board of Health *Heroin/Opioid Taskforce Recommendations* 10/20/2016

Food and Drug Administration- *Data and Clinical Considerations for Determining to Whom Naloxone Should be Distributed* White Oak, Maryland July 1, 2015

Subcommittee on Oversight and Investigations, United State House of Representatives, Committee on Energy and Commerce. Hearing on *Examining the Growing Problems of Prescription Drug and Heroin Abuse: State and Local Perspectives* Washington DC 3/26/2015

Washington State Pharmacy Association- *Opportunities for pharmacists to improve safety of controlled substance use by patients and communities* 11/13/14

WA State Drug Use Prevention Summit- Keynote- *Opiate Morbidity & Mortality: What's the Problem & What Can You Do About It?* 10/22/14

Washington State Medical Commission 2014 Educational Conference *Long-term Opioid Management of Chronic Pain: Trends, Risk, and Naloxone* 10/2/2014

American Academy of Forensic Sciences Annual Conference- Invited keynote lecture-*The Use of Pharmacoepidemiology in Forensic Toxicology- Municipal wastewater testing* 2/20/2014

State of the Art. Northwest Tribal Summit *Interventions to Reduce Opioid Overdose* December 12, 2013

Institute for Health Metrics and Evaluation *Municipal wastewater as a population measure of hidden health behaviors* <https://www.youtube.com/watch?v=U0-Ry-2UMI0> 10/30/2013

Testing the waters: first international multidisciplinary conference on detecting illicit drugs in wastewater Lisbon *Keynote presentation: Comparison of drug consumption estimates obtained from wastewater analysis and epidemiological studies.* 6–8 May 2013

OTHER ACTIVITIES

Practice activities

See activities including local, federal, and international committees and advisory boards; implementation grants/contracts; reports and lay articles above as well as selected activities below

- Developed and administer www.stopoverdose.org the reference page for Washington State on overdose prevention and response. Online training for lay people and professionals used in programs across the state prior to prescribing/dispensing naloxone. Audiences include lay people, EMS/fire departments, law enforcement, health care providers, pharmacists, addiction treatment providers, criminal justice, and librarians. Coordinate efforts with WA DOH and WA Health Care Authority. Seed funding Washington State Attorney General's office 2011. Funded by WA Health Care Authority 2012-Current
 - 705,464 page views lifetime of site, 66,837 page views July 2020-June 2021
- Developed and administer the WA State Drug Interactive Data Page <https://adai.uw.edu/wadata/> coordinating with WA Department of Health and Health Care Authority. Provides unique county and state data drug epidemiology data visualizations and interpretation. Funding WA State Health Care Authority 2015-Current.

- 77,436 page views lifetime of site 22,363 page views June 2020-July 2021,
- Developed and now administer www.learnabouttreatment.org a resource of evidence based and innovative practices for treating opioid and stimulant use disorder. Clinical models, protocols and training videos available. Audiences including people who use substances, the general public, family and friends, and diverse professionals. Funded by and coordinate efforts with WA Health Care Authority. 2020-Current.
 - 8,210 page views July 2020-June 2021
- WA State Syringe Services Program Surveys. I oversee this work in collaboration with WA Department of Health, Public Health-Seattle & King County and SSP's across the state. We oversee survey/interview design, implementation, analysis, reporting, and dissemination. Multiple graduate students have utilized data for theses and published manuscripts. Client surveying in odd years and qualitative interviews in even years. 2015-Current
- 2014 Healthy Youth Survey, WA State Division of Behavioral Health and Recovery and Department of Health, Survey design assistance, Autumn 2013
- Syringe Exchange Survey, Public Health-Seattle & King County, Survey design assistance, May-July 2013

Scientific review- Manuscripts (selected)

Health Affairs	2020-current
Journal of Substance Abuse Treatment	2020-current
Journal of Addiction Medicine	2018-current
New England Journal of Medicine	2016-current
Science of the Total Environment	2013-current
American Journal of Preventive Medicine	2011-current
Addiction	2010-current
American Journal of Public Health	2010-current
Drug and Alcohol Dependence	2008-current
Clinical Journal of Pain	2008-current
Environmental Science & Technology	2007-current

Conferences organized

- 2022 June 7 & 8, *Transforming our Communities: Sharing Innovations to Reduce Harms for People Who Use Drugs*. Virtual, WA State Audience. <https://adai.uw.edu/transforming-our-communities/>
- 2021 June 29 & 30, *Transforming our Communities: Supporting People Who Use Drugs*. Virtual, WA State Audience. <https://adai.uw.edu/transforming-our-communities/>
- 2020 June 22 & July 7, *Transforming our Communities: Health, Equity and Justice for People Who Use Drugs*. Virtual, WA State Audience. <https://adai.uw.edu/transforming-our-communities/>
- 2019 June 28, *Methamphetamine in Washington: Informing Policy and Research*. Seattle, WA <https://adai.uw.edu/methsummit/>
- 2015 May 5, *Heroin & Opioid Overdose Prevention Summit* Co-Hosted with the US Attorney's Office for Eastern Washington. Keynote Dr. Kathy Lofy, Health Officer, WA State Department of Health. Ellensburg, WA.
- 2015 February 10, *Heroin & Opioid Overdose Prevention Summit* Co-Hosted with the US Attorney's Office for Western Washington. Keynote Director Michael Botticelli Office of National Drug Control Policy, Executive Office of the President. Seattle, WA

Selected recent press coverage

(MORE THAN 100 MEDIA INTERVIEWS AND CITATIONS)

- *Naloxone is reaching more people than ever* CNN 01/13/2023
<https://www.cnn.com/2023/01/13/health/naloxone-more-accessible/index.html>
- *Washington Lawmakers Must Approve New Drug Sentence Rules or Eliminate Jail Time for Drug Possession* The Chronicle 01/08/2023 <https://www.chronline.com/stories/washington-lawmakers-must-approve-new-drug-sentence-rules-or-eliminate-jail-time-for-drug.306610>
- *Ongoing rise in fentanyl deaths highlights need for treatment alternatives* KUOW 12/02/2022
<https://www.kuow.org/stories/ongoing-rise-in-fentanyl-deaths-highlights-need-for-treatment-alternatives>
- *'It's happening with younger and younger people': UW expert talks about keeping youth safe amid rise in fentanyl use and overdoses* Spokesman Review Sept. 21, 2022
<https://www.spokesman.com/stories/2022/sep/21/its-happening-with-younger-and-younger-people-uw-e/>
 - *King County declares fentanyl a public health crisis.* KUOW 7/20/2022
- *As Fentanyl Overdoses Rise, How to Keep Loved Ones Safe.* New York Times 05/19/2022.
<https://www.nytimes.com/2022/05/19/well/live/what-is-fentanyl.html>
- *Fentanyl's lethal toll continues. Nearly 10 million pills were seized last year.* NPR 3/31/2022
- *'Trailblazer': A New Clinic in Centralia Hopes to Inform a More Effective Approach to the Opioid Crisis* Gather Church: Suboxone Clinic Part of Statewide Study with Promising Preliminary Results The Chronicle (Centralia, WA) 5/28/2021
- *Opioid treatment meds could be used more effectively in Washington, researchers say* KNKX 5/26/2021
- *Washington overdose deaths rise sharply. Fentanyl availability a main factor* KUOW, 02/09/2021
- *King County sees record spike in overdose deaths* KOMO TV, 01/20/2021
- *'There was nothing to help me': how the pandemic has worsened opioid addiction* The Guardian, 10/5/2020
- *Opioid overdoses on the rise during COVID-19 pandemic, despite telemedicine care* ABC News 08/24/2020
- *Fentanyl overdoses keep increasing in King County* Seattle Weekly, 02/27/2020
- *Walk-in clinics for opioid addiction offer meds first, fast* The New York Times, 12/18/2019
- *An opioid more deadly than fentanyl found on Seattle streets* KOMO News, 11/11/2019
- *Public health officials share information about fentanyl overdoses after deaths of teens* KNKX, 10/07/2019
- *Fewer people using opioids, and more want treatment* KOMO Radio, 10/01/2019
- *Overdose deaths continue to rise in King County. Here are two big reasons why* KUOW, 07/04/2019
- *Drug-related deaths continue to rise in King County* The Seattle Times, 07/02/2019

Op-Eds

- *Substance use is a health issue, not a legal one* The Seattle Times, By Caleb Banta-Green Nov. 30, 2022 <https://www.seattletimes.com/opinion/substance-use-is-a-health-issue-not-a-legal-one/>
- *Nation's opioid addiction treatment system during COVID-19 needs reform* The Hill, By Caleb Banta-Green, Regina LaBelle and Yngvild Olsen 03/17/2020
- *Take action to prevent fatal overdoses from heroin, prescription opiates* The Seattle Times, By Caleb Banta-Green, Joseph Merrill and T. Ron Jackson April 18, 2012